- Home
- TSHA vs TRVI Comparison
TSHA vs TRVI Comparison
Compare TSHA & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSHA
- TRVI
- Stock Information
- Founded
- TSHA 2019
- TRVI 2011
- Country
- TSHA United States
- TRVI United States
- Employees
- TSHA N/A
- TRVI N/A
- Industry
- TSHA Biotechnology: Pharmaceutical Preparations
- TRVI Biotechnology: Pharmaceutical Preparations
- Sector
- TSHA Health Care
- TRVI Health Care
- Exchange
- TSHA Nasdaq
- TRVI Nasdaq
- Market Cap
- TSHA 334.1M
- TRVI 363.7M
- IPO Year
- TSHA 2020
- TRVI 2019
- Fundamental
- Price
- TSHA $1.61
- TRVI $4.60
- Analyst Decision
- TSHA Strong Buy
- TRVI Strong Buy
- Analyst Count
- TSHA 8
- TRVI 8
- Target Price
- TSHA $6.63
- TRVI $9.31
- AVG Volume (30 Days)
- TSHA 2.1M
- TRVI 739.7K
- Earning Date
- TSHA 02-26-2025
- TRVI 03-19-2025
- Dividend Yield
- TSHA N/A
- TRVI N/A
- EPS Growth
- TSHA N/A
- TRVI N/A
- EPS
- TSHA N/A
- TRVI N/A
- Revenue
- TSHA $9,915,000.00
- TRVI N/A
- Revenue This Year
- TSHA N/A
- TRVI N/A
- Revenue Next Year
- TSHA N/A
- TRVI N/A
- P/E Ratio
- TSHA N/A
- TRVI N/A
- Revenue Growth
- TSHA N/A
- TRVI N/A
- 52 Week Low
- TSHA $1.19
- TRVI $2.30
- 52 Week High
- TSHA $4.32
- TRVI $5.05
- Technical
- Relative Strength Index (RSI)
- TSHA 46.14
- TRVI 62.80
- Support Level
- TSHA $1.46
- TRVI $3.93
- Resistance Level
- TSHA $1.76
- TRVI $4.14
- Average True Range (ATR)
- TSHA 0.15
- TRVI 0.29
- MACD
- TSHA 0.01
- TRVI 0.06
- Stochastic Oscillator
- TSHA 39.33
- TRVI 64.82
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.